Patents by Inventor Ming-Shi Chang

Ming-Shi Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy using an IL-20 antagonist and an immune checkpoint inhibitor
    Patent number: 11661450
    Abstract: Methods and compositions relating to combination therapy using an IL-20 antagonist and an immune checkpoint inhibitor are provided.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: May 30, 2023
    Assignee: LBL Biotechnology Inc.
    Inventor: Ming-Shi Chang
  • TREATING TISSUE FIBROSIS AND/OR INJURY AND/OR ORGAN FAILURE WITH INTERLEUKIN 24 OR INTERLEUKIN 20 ANTAGONIST
    Publication number: 20220378875
    Abstract: Methods of treating tissue fibrosis and/or injury and/or organ failure using an interleukin 24 (IL-24) protein or an interleukin 20 (IL-20) antagonist are provided.
    Type: Application
    Filed: October 28, 2020
    Publication date: December 1, 2022
    Inventor: Ming-Shi CHANG
  • Use of IL-20 antagonists for treating eye diseases
    Patent number: 11279755
    Abstract: Methods for treating eye diseases such as dry eye disease (DED) and age-related macular degeneration (AMD) using an IL-20 antagonist that blocks the signaling pathway mediated by IL-20, for example, an antibody that binds IL-20 or an IL-20 receptor.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: March 22, 2022
    Assignee: LBL Biotechnology, Inc.
    Inventor: Ming-Shi Chang
  • COMBINATION THERAPY USING AN IL-20 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR
    Publication number: 20210332121
    Abstract: Methods and compositions relating to combination therapy using an IL-20 antagonist and an immune checkpoint inhibitor are provided.
    Type: Application
    Filed: April 22, 2020
    Publication date: October 28, 2021
    Applicant: LBL Biotechnology Inc.
    Inventor: Ming-Shi CHANG
  • USE OF IL-20 ANTAGONISTS FOR TREATING EYE DISEASES
    Publication number: 20200048339
    Abstract: Methods for treating eye diseases such as dry eye disease (DED) and age-related macular degeneration (AMD) using an IL-20 antagonist that blocks the signaling pathway mediated by IL-20, for example, an antibody that binds IL-20 or an IL-20 receptor.
    Type: Application
    Filed: April 25, 2018
    Publication date: February 13, 2020
    Inventor: Ming-Shi CHANG
  • Use of IL-20 antagonists for treating pancreatic cancer
    Patent number: 9982043
    Abstract: Methods for treating pancreatic cancer using an IL-20 antagonist, which can be an antibody that binds IL-20 or an IL-20 receptor, thereby blocking the signaling pathway mediated by IL-20.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: May 29, 2018
    Assignee: National Cheng Kung University
    Inventor: Ming-Shi Chang
  • USE OF IL-20 ANTAGONISTS FOR TREATING PANCREATIC CANCER
    Publication number: 20170349656
    Abstract: Methods for treating pancreatic cancer using an IL-20 antagonist, which can be an antibody that binds IL-20 or an IL-20 receptor, thereby blocking the signaling pathway mediated by IL-20.
    Type: Application
    Filed: June 3, 2016
    Publication date: December 7, 2017
    Applicant: National Cheng Kung University
    Inventor: Ming-Shi Chang
  • TREATING LIVER DISEASES WITH INTERLEUKIN 24
    Publication number: 20170348389
    Abstract: Methods of treating liver diseases such as liver fibrosis using an interleukin 24 (IL-24) protein.
    Type: Application
    Filed: June 3, 2016
    Publication date: December 7, 2017
    Applicant: National Cheng Kung University
    Inventor: Ming-Shi Chang
  • Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
    Patent number: 9758575
    Abstract: Disclosed herein are antibodies capable of inhibiting canine vascular endothelial growth factor and uses thereof in treating a canine angiogenesis-related disorder such as a proliferative disease.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: September 12, 2017
    Assignee: Yung Shin Pharmaceutical Industrial Co. Ltd.
    Inventor: Ming-Shi Chang
  • Method of inhibiting adipogenesis with an IL-20 antibody
    Patent number: 9751949
    Abstract: Alleviating obesity in a subject (e.g., a human subject) having, obesity using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: September 5, 2017
    Assignee: National Cheng Kung University
    Inventors: Ming-Shi Chang, Yu-Hsiang Hsu
  • Humanized anti-IL-20 antibody and uses thereof
    Patent number: 9683036
    Abstract: Humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: June 20, 2017
    Assignee: National Cheng Kung University
    Inventors: Ming-Shi Chang, Naoya Tsurushita, Shankar Kumar
  • Use of IL-20 antagonists for alleviating spinal cord injury
    Patent number: 9512218
    Abstract: Alleviating neural injury, such as spinal cord injury, in a subject (e.g., a human subject) in need of the treatment using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: December 6, 2016
    Assignee: National Cheng Kung University
    Inventors: Ming-Shi Chang, I-Ming Jou
  • ANTIBODIES BINDING TO CANINE VASCULAR ENDOTHELIAL GROWTH FACTOR AND USES THEREOF IN TREATING CANINE ANGIOGENESIS-RELATED DISEASES
    Publication number: 20160289313
    Abstract: Disclosed herein are antibodies capable of inhibiting canine vascular endothelial growth factor and uses thereof in treating a canine angiogenesis-related disorder such as a proliferative disease.
    Type: Application
    Filed: April 6, 2015
    Publication date: October 6, 2016
    Applicant: Yung Shin Pharmaceutical Industrial Co. Ltd.
    Inventor: Ming-shi Chang
  • Treatment of inflammatory pain using IL-20 antagonists
    Patent number: 9376490
    Abstract: Reducing inflammatory pain in a subject having or being suspected of having an inflammatory pain using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: June 28, 2016
    Assignee: National Cheng Kung University
    Inventors: Ming-Shi Chang, Yen-Chen Liu, Meng-Ru Shen
  • Use of IL-20 antagonists for treating liver diseases
    Patent number: 9365652
    Abstract: Reducing liver fibrosis in a subject having or being suspected of having a liver disease using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: June 14, 2016
    Assignee: National Cheng Kung University
    Inventor: Ming-Shi Chang
  • Treatment of osteoarthritis using IL-20 antagonists
    Patent number: 9221904
    Abstract: The present disclosure provides methods for alleviating or delaying the onset of osteoarthritis in a subject in need of the treatment using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20, e.g., an anti-IL-20 antibody.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: December 29, 2015
    Assignee: National Cheng Kung University
    Inventor: Ming-Shi Chang
  • Humanized anti-IL-20 antibody and uses thereof
    Patent number: 9217031
    Abstract: The present disclosure provides humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: December 22, 2015
    Assignee: National Cheng Kung University
    Inventor: Ming-Shi Chang
  • TREATMENT OF INFLAMMATORY PAIN USING IL-20 ANTAGONISTS
    Publication number: 20150274821
    Abstract: Reducing inflammatory pain in a subject having or being suspected of having an inflammatory pain using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.
    Type: Application
    Filed: April 1, 2014
    Publication date: October 1, 2015
    Applicant: National Cheng Kung University
    Inventors: MING-SHI CHANG, YEN-CHEN LIU
  • Methods for treating osteoporosis with anti-IL-20 receptor antibodies
    Patent number: 9127066
    Abstract: Treating a disorder (e.g., osteoporosis, renal failure, or diabetic nephropathy) associated with a signaling pathway mediated by IL-20 receptor with an agent that suppresses IL-20 receptor activity, e.g., an antibody that neutralizes IL-20 receptor via binding to IL-20R1, an antisense nucleic acid that suppresses expression of IL-20R1, a small molecule that inhibits IL-20 receptor activity, or a dominant negative mutant of IL-19, IL-20, or IL-24.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: September 8, 2015
    Assignee: National Cheng Kung University
    Inventor: Ming-Shi Chang
  • Humanized Anti-IL-20 Antibody And Uses Thereof
    Publication number: 20150118711
    Abstract: Humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.
    Type: Application
    Filed: October 29, 2013
    Publication date: April 30, 2015
    Applicant: NATIONAL CHENG KUNG UNIVERSITY
    Inventors: MING-SHI CHANG, NAOYA TSURUSHITA, SHANKAR KUMAR